Literature DB >> 10194772

The acute inflammatory response in CNS following injection of prion brain homogenate or normal brain homogenate.

S Betmouni1, V H Perry.   

Abstract

The neuropathological hallmarks of end-stage prion disease are vacuolation, neuronal loss, astrocytosis and deposition of PrPSc amyloid. We have also shown that there is an inflammatory response in the brains of scrapie-affected mice from 8 weeks post-injection. In this study we have investigated the acute CNS response to the intracerebral injection of scrapie-affected brain homogenate. The ME7 strain of scrapie (Neuropathogenesis Unit, Edinburgh) was used, and control mice were injected with brain homogenate derived from normal C57BL/6 J mice. One microlitre of 10% w/v ME7 (n = 33) and normal brain homogenate (n = 28) was injected stereotaxically into the right dorsal hippocampus. Cryostat sections of brains taken at 1, 2, 5, 7, 14 and 28 days post-injection were examined histologically for neuronal loss, and immunocytochemically to study the inflammatory response. This study shows that ME7 is not acutely neurotoxic in vivo. There is also no difference (ANOVA) in the inflammatory response, which peaked between 2 and 5 days and resolved by 4 weeks after intracerebral injection of either ME7 or normal brain homogenate. The well circumscribed inflammatory response seen previously at 8 weeks is therefore a consequence of a disease process rather than a surgical artefact. This disease process may be related to a localized accumulation of PrPSc sufficient to stimulate an inflammatory response which in turn may contribute to neuronal loss. The role of the inflammatory response in chronic neurodegeneration can be usefully studied using this mouse model of prion disease, and this will undoubtedly shed light on the pathogenic mechanisms underlying other chronic neurodegenerative diseases.

Entities:  

Mesh:

Year:  1999        PMID: 10194772     DOI: 10.1046/j.1365-2990.1999.00153.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  13 in total

1.  Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease.

Authors:  Colm Cunningham; David C Wilcockson; Delphine Boche; V Hugh Perry
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 2.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

3.  Early behavioral changes and quantitative analysis of neuropathological features in murine prion disease: stereological analysis in the albino Swiss mice model.

Authors:  Roseane Borner; João Bento-Torres; Diego R V Souza; Danyelle B Sadala; Nonata Trevia; José Augusto Farias; Nara Lins; Aline Passos; Amanda Quintairos; José Antônio Diniz; Victor Hugh Perry; Pedro Fernando Vasconcelos; Colm Cunningham; Cristovam W Picanço-Diniz
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

4.  Accelerated prion disease in the absence of interleukin-10.

Authors:  Alana M Thackray; Andrew N McKenzie; Michael A Klein; Angus Lauder; Raymond Bujdoso
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies.

Authors:  Hanna Lewicki; Antoinette Tishon; Dirk Homann; Honoré Mazarguil; Françoise Laval; Valerie C Asensio; Iain L Campbell; Stephen DeArmond; Bryan Coon; Chao Teng; Jean Edouard Gairin; Michael B A Oldstone
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Prion protein expression differences in microglia and astroglia influence scrapie-induced neurodegeneration in the retina and brain of transgenic mice.

Authors:  Lisa Kercher; Cynthia Favara; James F Striebel; Rachel LaCasse; Bruce Chesebro
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

7.  Role of Erk1/2 activation in prion disease pathogenesis: absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression.

Authors:  Rachel A LaCasse; James F Striebel; Cynthia Favara; Lisa Kercher; Bruce Chesebro
Journal:  J Neuroimmunol       Date:  2008-04-08       Impact factor: 3.478

8.  Prion potentiation after life-long dormancy in mice devoid of PrP.

Authors:  Davy Martin; Fabienne Reine; Laetitia Herzog; Angélique Igel-Egalon; Naima Aron; Christel Michel; Mohammed Moudjou; Guillaume Fichet; Isabelle Quadrio; Armand Perret-Liaudet; Olivier Andréoletti; Human Rezaei; Vincent Béringue
Journal:  Brain Commun       Date:  2021-04-28

9.  Early Hippocampal Synaptic Loss Precedes Neuronal Loss and Associates with Early Behavioural Deficits in Three Distinct Strains of Prion Disease.

Authors:  Kathryn J Hilton; Colm Cunningham; Richard A Reynolds; V Hugh Perry
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

Review 10.  Prion disease and the innate immune system.

Authors:  Barry M Bradford; Neil A Mabbott
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.